Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psychopharmacologic Aspects of Motor Slowing in Schizophrenia
NCT00018668Phase 4Completed
- Sponsor
- United States Department of Veterans Affairs
- Start
- Oct 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of risperidone, olanzapine and quetiapine in schizophrenia (3 arms), sponsored by United States Department of Veterans Affairs. Primary endpoint: Cognitive or parkinsonian components of motor slowing at 8 weeks. Started Oct 2000; status: completed.
02
Drugs
risperidoneolanzapinequetiapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00018668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00018668.